Key Takeaways
- • Arlington Capital is acquiring Gooch & Housego in a £338 million take-private transaction, removing the optical technologies company from public markets.
- • Gooch & Housego operates across three core verticals: aerospace and defense, industrial and telecom, and life sciences, positioning it within defense-adjacent supply chain infrastructure.
- • The deal represents a consolidation of a specialized optical design, testing, and manufacturing business into a private equity ownership structure, typical of the sector consolidation trend in advanced manufacturing.
Summary
Arlington Capital is proceeding with an acquisition of Gooch & Housego for £338 million, taking the publicly traded optical technologies manufacturer private. The transaction represents a significant move in the specialized manufacturing sector, where Arlington is acquiring a company with established capabilities across multiple high-value end markets.
Gooch & Housego is a vertically integrated optical technology company with focus on design, testing, and manufacturing. Its customer base spans three primary sectors: aerospace and defense (a resilient end market supported by elevated government spending); industrial and telecommunications infrastructure; and life sciences, which encompasses medical device and diagnostic applications. This diversified vertical exposure positions the company across both discretionary and mission-critical spending categories.
The £338 million valuation reflects current market conditions for specialized manufacturers with government and institutional customer bases. The take-private structure removes public market disclosure obligations and provides Arlington with operational flexibility to pursue consolidation strategies within the optical technologies and advanced manufacturing space.
Gooch & Housego is a vertically integrated optical technology company with focus on design, testing, and manufacturing. Its customer base spans three primary sectors: aerospace and defense (a resilient end market supported by elevated government spending); industrial and telecommunications infrastructure; and life sciences, which encompasses medical device and diagnostic applications. This diversified vertical exposure positions the company across both discretionary and mission-critical spending categories.
The £338 million valuation reflects current market conditions for specialized manufacturers with government and institutional customer bases. The take-private structure removes public market disclosure obligations and provides Arlington with operational flexibility to pursue consolidation strategies within the optical technologies and advanced manufacturing space.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.